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Background: Alzheimer’s disease (AD) and other forms of dementia are among the
most common causes of disability in the elderly. Dementia is often accompanied by
depression, but specific diagnostic criteria and treatment approaches are still lacking.
This study aimed to gather expert opinions on dementia and depressed patient
management to reduce heterogeneity in everyday practice.
Methods: Prospective, multicenter, 2-round Modified Delphi survey with 53 questions
regarding risk factors (11), signs and symptoms (7), diagnosis (8), and treatment (27) of
depression in dementia, with a particular focus on AD. The questionnaire was completed
by a panel of 37 expert physicians in neurodegenerative diseases (19 neurologists, 17
psychiatrists, and 1 geriatrician).
Results: Consensus was achieved in 40 (75.5%) of the items: agreement in 33
(62.3%) and disagreement in 7 (13.2%) of them. Among the most relevant findings,
depression in the elderly was considered an early sign (prodromal) and/or a dementia
risk factor, so routine cognitive check-ups in depressed patients should be adopted,
aided by clinical scales and information from relatives. Careful interpretation of
neuropsychological assessment must be carried out in patients with depression
as it can undermine cognitive outcomes. As agreed, depression in early AD is
characterized by somatic symptoms and can be differentiated from apathy by
the presence of sadness, depressive thoughts and early-morning awakening. In
later-phases, symptoms of depression would include sleep-wake cycle reversal,
aggressive behavior, and agitation. Regardless of the stage of dementia, depression
would accelerate its course, whereas antidepressants would have the opposite effect.
Those that improve cognitive function and/or have a dual or multimodal mode of
action were preferred: Duloxetine, venlafaxine/desvenlafaxine, vortioxetine, tianeptine,
and mirtazapine. Although antidepressants may be less effective than in cognitively
healthy patients, neither dosage nor treatment duration should differ. Anti-dementia
cholinesterase inhibitors may have a synergistic effect with antidepressants.
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Exercise and psychological interventions should not be applied alone before any
pharmacological treatment, yet they do play a part in improving depressive symptoms in
demented patients.
Conclusions: This study sheds light on several unresolved clinical challenges regarding
depression in dementia patients. Further studies and specific recommendations for this
comorbid patient population are still needed.
Keywords: Alzheimer’s disease, dementia, depression, prodromal symptoms, cholinesterase inhibitors, dual and
multimodal antidepressants, precognitive action, consensus
INTRODUCTION
Aging is the strongest risk factor associated with dementia. Not
surprisingly, with the aging of the world’s population, the number
of people living with dementia worldwide is expected to rise to 82
million in 2030 and almost double in 2050. Thus, considering that
dementia is one of the most common causes of disability among
the elderly, such estimates will have a physical, emotional and
financial impact on dementia sufferers as well as their caregivers
and relatives. The increased global economic and healthcare
system burden cannot be dismissed either (1).
Chronic and progressive cognitive impairment is the clinical
hallmark of dementias, namely Alzheimer’s disease (AD) or
other less common types such as vascular, Lewy body, and
frontotemporal dementia (FTD) (1). Neuropsychiatric symptoms
like depression often accompany and/or precedes dementia onset
(1, 2). A recent meta-analysis determined that the prevalence of
major depression was 15.9% and 14.8% in all-cause dementia and
in AD, respectively (3). More strikingly, around one third of the
adult population with depression is diagnosed with concomitant
mild cognitive impairment (MCI) (4). In fact, it is thought that
the presence of depression favors the conversion of MCI into AD
later in life (5).
Given these known associations between depression and
AD and the increasing rates of dementia, medical and
community care services need to adjust to the specific needs
and management of comorbid patients. However, depression
in AD is still underdiagnosed and, therefore, undertreated
most likely as a consequence of the lack of consistent
diagnostic criteria to assess depression in this context (6).
This, in turn, is challenged by the overlap of some symptoms.
There are also discrepancies in reports between caregivers
and patients, who tend to underestimate their symptoms of
depression. On the other hand, depression recognition by
caregivers varies depending on their level of stress and personal
circumstances (7).
Once the diagnosis has been established, treatment regimens
for depressed dementia patients are often extrapolated from
clinical practice guidelines (CPG) or consensus on either
AD or depression, which contributes to patient management
heterogeneity (6). Besides, more controlled studies are needed
to develop specific CPG recommendations for concurrent
AD and depression. Only about a fifth of clinical trials of
AD interventions considers neuropsychiatric symptoms like
depression as a primary endpoint (8).
The aim of this Delphi study is to help homogenize the
clinical care of patients with depression and dementia. Emphasis
is placed on AD as it is the most frequent type of dementia.
Since all consulted experts have broad experience in managing
such patients, we expect to obtain specific diagnostic hints
otherwise not included in current CPGs. We also suspect
that prescription advice may not completely overlap with
recommendations in the published guidelines for depression or
dementia for this particular subgroup of patients for the reasons
already mentioned.
MATERIALS AND METHODS
Delphi Study Design and Methodology
This is a Modified Delphi study (9–11) based on a two-round
closed-ended online survey. A total number of 53 items were
grouped into 4 sections regarding risk factors (11), signs and
symptoms (7), diagnosis (8), and treatment (12) of depression in
AD and other dementias.
Participants responded to the 53 items of the questionnaire
in the first round. Upon revision of the statistical results and
comments made by panelists, they reconsidered the items for
which consensus could not be reached in the second one. To
do so, they anonymously assessed their level of agreement with
every statement using a single ordinal 9-point Likert scale. A
score value ranging from 1 to 3 was used to express disagreement
(the lower the value, the stronger the disagreement); 4 to 6,
half-way between agreement and disagreement (having a value
of 4 demonstrated a tendency toward disagreement); and 7 to
9, agreement with the item (the higher the value, the stronger
the agreement).
Consensus on each item was decided according to the
RAND/UCLA criteria, i.e., when less than one third of the actual
number of participants rates the item with a value outside the 3-
point region which contains the median (9, 11, 13). For instance,
given a median of 8, consensus agreement is obtained if <12
participants of this Delphi study (N = 37) rate the item outside
the 7–9 region.
Participants
The study was led by a Scientific Committee composed of 8
eminent physicians (4 psychiatrists and 4 neurologists) in the
field of neurodegenerative diseases in the elderly. Duties assigned
to the Committee were: Designing the study and protocol,
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writing the questionnaire, performing the statistical analysis, and
analyzing and interpreting the results.
Although no formal sample size calculation is available for
Delphi studies, a total number of 30–40 panelists was initially
estimated as appropriate according to standard recommended
practices (14). Finally, 37 physicians (27 men and 10 women)
were invited and all medical specialties involved in the care of
AD patients were covered (19 neurologists, 17 psychiatrists, and 1
geriatrist, whichmirrors the distribution in the real-world clinical
practice). All of them have a distinct curriculum in the field, were
considered experts by their peers during the snowball selection
process (15), and belong to tertiary hospitals with a spread
geographical distribution throughout the country. Processing
of personal information complies with all data protection and
privacy laws and regulations.
Statistical Analysis
Interpretation of the results was carried out using mean values
and confidence intervals for the average at a 95% confidence
level. Agreement or disagreement with each item depended on
average values being closer to 9 or 1, respectively. Confidence
intervals were informative of both unanimity of opinions and
whether consensus agreement or disagreement could be reached
for a given item. For instance, intervals containing the value 5,
which corresponded to “neither agreement nor disagreement,”
did not provide a consensus answer. In these cases, a descriptive
reasoning was provided to participants.
RESULTS
The Delphi survey was presented to the panel of experts in
two successive rounds. In the first one, 33 (62.3%) items out
of 53 reached consensus, rising to 40 (75.5%) in the second
round. Overall, participants reached consensus to agree with
33 (62.3%) statements and to disagree with another 7 (13.2%).
Approximately, one quarter of the questionnaire could not obtain
consensus (13 items; 24.5%) (Table 1, Figure 1).
Tables 2–5 show all Delphi statements and the resulting
expert opinions toward each of them at the end of the study:
No consensus or consensus, and if so, either agreement or
disagreement. Items were classified into 4 categories attending to
distinct clinical domains related to depression in AD. Regarding
its etiology and potential risk factors, respondents agreed with
most assertions [agreement in 9 items (16.9%), disagreement in
1 (1.9%), and no consensus in 1 (1.9%); Table 2]. The other
domains were more controversial but agreement was still the
predominant choice: Clinical manifestations [agreement in 4
items (7.6%) and no consensus in 3 (5.7%); Table 3]; diagnosis
[agreement in 5 items (9.4%), disagreement in 2 (3.8%), and no
consensus in 1 (1.9%); Table 4], and treatment [agreement in 15
items (28.3%), disagreement in 4 (7.6%), and no consensus in 8
(15.1%); Table 5] (Table 1).
DISCUSSION
Research reports and medical guidelines specifically addressing
depression in AD are scarce. Here, we present applicable expert
opinions on the management of older individuals suffering
or suspected to suffer from both clinical entities. The main
limitation of the study is the local origin of panelists, which could
reflect a country-specific approach. However, this also implies
higher homogeneity among surveyed participants and therefore
higher consistency of results, which reinforces the findings
presented. Other limitations of the study are common with other
Delphi studies, yet these are substantially restrained using the
modified version, based on a two-round closed-ended survey. In
short, in the Modified Delphi technique, items have already been
pre-selected by a committee of experts based on their competent
profile and revision of the available literature. Consequently,
both the clinical relevance of questions addressed and consensus
response rates are higher. Other assets are the possibility to offer
controlled feedback to participants and assuring the anonymity
of participants (11).
Due to the large number of items in the questionnaire, results
are discussed in a question-answer format for ease of reading.
Also, consensus and no consensus statements are contrasted
with available depression, dementia, or mental health CPG
recommendations as well as published evidence. Figure 2 shows
the take-home messages of the present study, which may be used
to inform clinical evaluation and aid decision making.
I. Etiology and Risk Factors for Depression
in Dementia Patients
Does Late-Onset Depression Favor Dementia
Development?
There was consensus in all statements regarding late-onset
depression and the likelihood of subsequent dementia (Table 2;
S4, S5, and S11). Thus, the majority of respondents reckoned that
depression that initiates in later phases of adulthood and into old
age increases the risk of suffering from dementia (Table 2; S4).
In the same line, experts came to the agreement that depression
should be considered a prodromal symptom of dementia and
not a stand-alone clinical entity (Table 2; S5). For this reason,
a regular follow-up of depressed patients over 50 is paramount,
even in the advent of symptom improvement (Table 2; S11).
The relationship between dementia and depression is
supported by a growing body of evidence and the positioning
of medical societies such as the European Federation of
Neurological Societies (EFNS), the National Institute for
Health and Care Excellence (NICE), the American Psychiatric
Association (APA), and the World Federation of Societies of
Biological Psychiatry (WFSBP) (16–21). Their respective CPGs
recommend regular depressive symptom appraisal in elderly
patients with dementia and assessment of other secondary
causes (6), but these recommendations do not explicitly include
following up on depressed patients at risk of dementia (i.e., before
the diagnosis of dementia) to anticipate its onset.
Since the term “Behavioral and Psychological Symptoms
in Dementia” (BPSD) was coined by the International
Psychogeriatric Association (IPA) (2), many studies
have demonstrated the existence of clinically-significant
neuropsychiatric symptoms (including affective symptoms)
prior to or over the course of dementia. Besides, the affective
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Total consensus No consensus
First round, n (%) 33 (62.3%) 0 (0%) 33 (62.3%) 20 (37.7%)
Second round, n (%) 33 (62.3%) 7 (13.2%) 40 (75.5%) 13 (24.5%)
Section I—Etiology and risk factors for depression in dementia patients, n (%) 9 (16.9%) 1 (1.9%) 10 (18.9%) 1 (1.9%)
Section II—Clinical manifestations of depression in Alzheimer’s disease and
other dementias, n (%)
4 (7.6%) 0 (0%) 4 (7.6%) 3 (5.7%)
Section III—Diagnostic criteria for depression in Alzheimer’s disease and other
dementias, n (%)
5 (9.4%) 2 (3.8%) 7 (13.2%) 1 (1.9%)
Section IV—Antidepressant treatment for dementia and Alzheimer’s disease
patients, n (%)
15 (28.3%) 4 (7.6%) 19 (35.8%) 8 (15.1%)
All statements. N = 53.
FIGURE 1 | Degree of consensus, agreement, and disagreement among all participants of the Delphi study. N = 53 statements.
dimension has been included in the Mild Behavioral Impairment
(MBI) diagnostic criteria and its associated MBI-Checklist
(MBI-C) scale, which aims at improving the identification of
patients at risk of dementia (22, 23).
Specifically, depression appears to be a dementia risk
factor (cause) or an early sign (prodrome) of an underlying
neurodegenerative disease typically associated with AD and other
forms of dementia (12, 24–28). This interconnection seems
to be dependent on age, depression severity, and success of
antidepressant treatment (29, 30). In a large-cohort retrospective
work by Barnes et al., the risk of dementia in patients with
depressive symptoms greatly differs between midlife and late-life
individuals (20% vs. 70%, respectively) (29). Results of another
longitudinal study showed that the group of patients with a high-
intensity and increasing depressive symptom trajectory were
predisposed to develop dementia throughout the study period
(more than a decade). This also underscores the importance of
regular check-ups of patients with depressive symptoms over
one-time assessments of depression in order to infer dementia
risk (31).
Do Depressive Symptoms Worsen or Accelerate
Dementia Progression?
In the context of neurodegenerative processes, experts agreed on
the role of depression not only as a dementia initiation risk factor
but as a progression enhancer (Table 2; S10). Conversely, treating
the symptoms of depression that appear over the course of a
neurodegenerative process would affect favorably its evolution
(Table 2; S8).
Whether depressive symptom trajectory influences the
progression of AD and other dementias has not been fully
elucidated, and data from different authors have led to
contradictory conclusions (32–35). However, there is mounting
evidence to support common etiological mechanisms between
depression and neurodegenerative pathologies (32, 36–38),
therefore it seems plausible to suspect on an additive effect
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S1 Stress and/or depression in caregivers worsen symptoms of depression in patients
with dementia
S2 Social environment is determining for the onset of depression in dementia
S3 In the context of neurological diseases associated with dementia, depression is
fundamentally reactive, and it depends on individual ways of becoming ill
S4 Late-onset depression increases the risk of dementia
S5 Depression that starts developing a few years prior to dementia onset constitutes a
prodromal symptom and not an independent disorder
S6 In elderly patients, depressive episodes accompanied by subjective memory loss
complaints increase the risk of dementia
S7 Greater vascular damage increases the risk of depression in dementia
S8 Treatment of depression in the context of dementia positively affects the course of the
latter
S9 Disclosing the diagnosis of dementia to older patients increases the likelihood of
clinically relevant depression
—
S10 Depression accelerates dementia progression
S11 Given the link between depression and neurodegenerative diseases, patients over 50
with any symptoms of depression must be followed regularly, even if they show signs
of improvement







S12 The most specific symptoms of depression in AD are the ones that define the
so-called somatic syndrome of depression (daily mood fluctuations, early-morning
awakening, psychomotor retardation, or anorexia with weight loss)
S13 In late-stage dementia, symptoms of depression include sleep-wake cycle reversals,
aggression, and agitation
S14 Apathy is a depression risk factor in dementia —
S15 The existence of depression in AD patients undermines the neuropsychological
assessment
S16 In advanced AD, the term “depression” should be replaced by “symptoms of
depression”
S17 In depressive and dementia patients, autolytic behavior is only exceptional —
S18 Depressive pseudodementia is a useful clinical concept and should be preserved. —
AD, Alzheimer’s disease.
of depressive symptoms in AD. Genetic variations and
neurobiological factors such as cerebrovascular disease,
proinflammatory cytokines, cortisol and increased amyloid
production, and accumulation may confer comorbidity risk
(28, 37, 39). From a structural and functional point of view, a
recent systematic review by Rashidi-Ranjbar et al. concluded
that overlapping alterations in both frontal-executive and
corticolimbic circuits, as well as alterations of global brain
topology can be observed in many studies analyzing late-life
depression and mild cognitive impairment patient samples (38).
There are also doubts as to whether antidepressants can
reverse the deleterious effects of depression on dementia due
to the scarcity of specifically driven studies. Long-term use
of selective serotonin reuptake inhibitors (SSRIs) may delay
dementia development in patients with MCI and depression
(40). However, a previous meta-analysis had calculated a 2-
fold increased risk of suffering from cognitive impairment or
Alzheimer’s dementia upon antidepressant drug usage, especially
if this is started before age 65 (41), however this effect may be
linked to depression itself rather than its treatment.
What Is the Clinical Relevance of Subjective Memory
Loss Complaints in Depressed Older Patients?
The co-occurrence of depressive episodes and subjective memory
loss complaints was also considered a dementia predisposition
factor by the panel of experts (Table 2; S6).
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S19 Information provided by the relatives is not very precise for the diagnosis of
depression in dementia
S20 Sadness, depressive cognitions, and early-morning awakening distinguish depression
from apathy in AD
S21 Structural neuroimaging is not useful for diagnosing depression in AD patients
S22 Functional neuroimaging (SPECT or, preferentially, brain PET) can be used to
distinguish primary depression from depression secondary to AD
—
S23 Depression is a rare event in FTD
S24 Differential depression diagnostic criteria are needed for the distinct diseases that can
present with dementia (e.g., AD, PD, FTD, etc.)
S25 Differential depression diagnostic criteria are needed in the distinct stages of the
dementia syndrome
S26 CSDD is a useful scale for detecting and assessing depression in older dementia
patients in the daily clinical practice
AD, Alzheimer’s disease; CSDD, Cornell Scale for Depression in Dementia; FTD, frontotemporal dementia; PD, Parkinson’s disease; PET, positron emission tomography; SPECT, single
photon emission computed tomography.
In connection to this consensus statement, it is known
that depression favors the transition from normal cognition to
MCI, and from MCI to dementia (5, 42–44). In fact, around
30% of older adults with depression are also diagnosed with
MCI (4). For this reason, repeated cognitive assessment in
already diagnosed depressed patients, and especially in patients
with depressive pseudodementia, is strongly supported by
experts and some available published evidence as subsequent
deterioration during the course of depression constitutes a
prognosis factor and a clinical marker for dementia onset (24, 45).
Nevertheless, some caution must be taken on such cognitive
evaluation since depression itself may interfere with it (Section II.
Clinical manifestations of depression in Alzheimer’s disease and
other dementias).
What Factors Are Involved in the Etiology of
Depression in the Context of Dementia?
Depression that arises in the context of dementia was not
considered a purely emotional reactive mental disorder (Table 2;
S3), however there was consensus on the importance of social
environment to its onset (Table 2; S2), including stress and/or
depression in caregivers, which was believed to enhance their
depressive symptomatology in a vicious circle (Table 2; S1).
Consensus was also achieved on the pernicious effect that
vascular damage has on the affective domain of these patients
(Table 2; S7). On the contrary, there was no consensus on
whether apathy also contributes to depression too (Table 3; S14).
As mentioned earlier, both disturbances appear to be linked
through common neurobiological mechanisms (32, 36–39), but
it is still unclear whether depression is an etiological factor, a
prodromal symptom, a coincidental finding or a secondary effect
of dementia (12, 27, 28). Thus, manifestations of depression
may not precede cognitive decline but arise in the presence of
clinically overt dementia (46, 47).
In this scenario, and according to the results presented
here, neither environmental stressors nor the personal way
in which an individual becomes sick play a central role in
depression development in dementia compared to cognitively
healthy individuals (Table 2; S3). Instead, neurobiological
considerations related to the dementing disorder may be
more preponderant here. As such, pathophysiological events
such as increased vascular load and/or neurodegenerative
processes may lead to structural and functional brain damage,
thereby jeopardizing cognitive function and the affective
domain (37, 46, 48, 49). There are, nonetheless, several
studies that call into question the “vascular depression
hypothesis,” i.e., depression secondary to cerebrovascular
disease (50, 51).
As discussed later on Section III (Diagnostic criteria
for depression in Alzheimer’s disease and other dementias),
comorbid apathy in dementia patients requires differential
diagnosis as an independent clinical entity. Although being
highly frequent in AD patients with depression, it can be present
in non-depressed patients too. Interestingly, previous reports
have shown that the frequency of apathy (but not depression)
increase in time as dementia progresses (52, 53). Altogether, these
data suggest that apathy in dementia may not predispose or be
linked to depression.
How Important Is Disclosing the Diagnosis of
Dementia to Older Patients in Regard to Depression
Risk?
This is a controversial subject and such a question could not reach
consensus among experts (Table 2; S9).
Whether the diagnosis of dementia should be disclosed
to patients or not has triggered much ethical debate as
they are exposed to the unpleasant reality of suffering from
a degenerative disease with no breakthrough therapeutic
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S27 Physical activity improves symptoms of depression in dementia
S28 Antidepressants are efficacious drugs for treating depression in AD
S29 Combining antidepressants with ChEIs has a synergistic effect on the treatment of
depression in AD patients
S30 Tianeptine is an efficacious drug in AD patients with depression
S31 Psychological interventions like increasing social contact, reminiscence therapy, and
cognitive rehabilitation are efficacious approaches to treating depression in dementia.
S32 Non-pharmacological approaches to depression associated with dementia are the
best initial option
—
S33 Patients suffering from both depression and AD should be treated with a ChEI before
prescribing them any antidepressants
S34 Patients suffering from both depression and AD should be treated with an
antidepressant before prescribing them a ChEI
—
S35 Patients suffering from both depression and AD should be treated with an
antidepressant and a ChEI at the same time
—
S36 Multiple-action antidepressants are the preferred choice for the treatment of
depression in AD patients
S37 ChEIs have a positive effect on depression in AD
S38 Memantine has a positive effect on depression in AD —
S39 In patients with depression and cognitive decline, diagnosis of AD should wait until
symptoms of depression and cognitive impairment have been followed upon
antidepressant prescription
S40 Antidepressants that improve cognitive function (tianeptine, vortioxetine, and
duloxetine) are the preferred choice for the treatment of depression in AD patients
S41 Treatment with antidepressants is less effective in older patients with AD than
without it
S42 Antidepressants should be prescribed at lower doses in AD patients compared to
non-cognitively impaired older patients
S43 ECT is a recommended therapeutic option for the treatment of refractory depression
in dementia patients
—
S44 TCAs are not to be used in patients with AD and depression
S45 SSRIs are not to be used in dementia patients with depression and significant levels
of apathy as they can worsen the latter
—
S46 Bearing in mind their specific efficacy and tolerability in AD, SSRIs are a good
therapeutic option for depression in this context
S47 Bearing in mind their specific efficacy and tolerability in AD, dual and multimodal
drugs are a good therapeutic option for depression in this context
S48 Bearing in mind their specific efficacy and tolerability in AD, mirtazapine is a good
therapeutic option for depression in this context
S49 Bearing in mind their specific efficacy and tolerability in AD, bupropion is a good
therapeutic option for depression in this context
—
S50 Bearing in mind their specific efficacy and tolerability in AD, nortriptyline is a good
therapeutic option for depression in this context
S51 Bearing in mind their specific efficacy and tolerability in AD, agomelatine is a good
therapeutic option for depression in this context
—
S52 Bearing in mind their specific efficacy and tolerability in AD, tianeptine is a good
therapeutic option for depression in this context
S53 In general, the duration of treatment with antidepressants should be shorter in AD
patients than in non-cognitively impaired older patients
AD, Alzheimer’s disease; ChEIs, cholinesterase inhibitors; ECT, electroconvulsive therapy; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
options. As discussed in the next section (Section II. Clinical
manifestations of depression in Alzheimer’s disease and other
dementias), some authors have suggested that sharing the
diagnosis with them would increase suicidal risk (54, 55). Other
studies suggest though that self-awareness of cognitive and
functional impairment is only associated with dysthymia but not
major depression (7). From this unresolved controversy and the
lack of consensus in this Delphi questionnaire it follows that
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FIGURE 2 | Key messages of the study. Consensus was reached on several fundamental statements regarding the relationship between late-onset depression and
subsequent dementia (A) and depression in older individuals already diagnosed with dementia (B). AD, Alzheimer’s disease; ChEIs, cholinesterase inhibitors; CSDD,
Cornell Scale for Depression in Dementia; FTD, frontotemporal dementia; PD, Parkinson’s disease; SSRIs, selective serotonin reuptake inhibitor.
physicians should be encouraged to individually assess the best
way and moment to deliver such information to the patient.
II. Clinical Manifestations of Depression in
Alzheimer’s Disease and Other Dementias
Is the Concept of Depressive Pseudodementia
Clinically Useful?
No consensus could be reached regarding the clinical utility of
the concept of “depressive pseudodementia,” i.e., the presence of
important cognitive symptoms inherent to depression, especially
in the elderly (Table 3; S18) (56).
These inconclusive results may mirror the general skepticism
surrounding the appropriateness of the term and its clinical value
(45). In support of it, and as already stated before, depression
is often involved in the progression of MCI into full-blown
dementia (5, 42–44), so depressive pseudodementia can have
prognostic implications in depressed patients who complain
about subjective memory loss. Also, the use of this term can aid
differential diagnosis as depression-related cognitive symptoms
(pseudodementia) may be confused with dementia and produce
false positives (45).
Does the Presence of Depression Interfere With
Neuropsychological Assessment in AD Patients?
Experts agreed that symptoms of depression undermine
neuropsychological test results in patients with AD (Table 3;
S15) and so neuropsychological assessment should wait until
antidepressant treatment outcomes can be observed in regard to
affective and cognitive symptoms (Table 5; S39).
In accordance with the previous question, frontal and
prefrontal executive deficit is the main cognitive symptom
specifically attributed to depression in the elderly over memory,
language, and visuospatial impairment (45). Thus, low cognitive
performance in depressed adults can be an artifact for AD
diagnosis. For this reason, it seems convenient to postpone it
until adequate treatment of depression has been applied and
patient’s symptomatology has been followed over time: Absence
of cognitive improvement upon depressive symptom remission
would pinpoint an ongoing neurodegenerative process; a
partial cognitive recovery would be indicative of either a partial
depression remission or a certain degree of neurodegeneration,
whereas a complete cognitive remission would correspond
to a previous pseudodementia diagnosis with no
added dementia.
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Which Are the Most Specific Signs and Symptoms of
Depression in AD?
Respondents agreed that the specific clinical manifestations of
depression in early AD are the ones under the umbrella of the so-
called somatic syndrome, which is typically found in the general
adult population with depression: Daily mood fluctuations, early-
morning awakening, psychomotor retardation, and anorexia
with weight loss (Table 3; S12). In contrast, as the course of
AD advances, the somatic syndrome is replaced by behavioral
symptoms such as aggression, agitation, and reversal of the sleep-
wake cycle (Table 3; S13). Current CPGs fail to provide clear and
specific diagnostic guidance for this subset of patients (16–20, 57,
58).
Is It Appropriate to Use the Term “Depression” in
Older Patients With Advanced AD?
In clear connection with the question above, experts
unanimously recommended talking about “symptoms of
depression” instead of “depressive disorder” (Table 3; S16) due
to the lack of depression-specific diagnostic criteria in the later
stages of AD (Section III. Diagnostic criteria for depression in
Alzheimer’s disease and other dementias).
Is Depression Commonly Reported in Other Less
Frequent Types of Dementia?
When asked about FTD patients, respondents refused the
idea that depression is a rare symptom in these cases
(Table 4; S23).
In line with these results, a very recent systematic review
on neuropsychiatric symptoms in different types of dementia
found that, together with AD, FTD shows the highest prevalence
of depression (59). Apart form that, given the almost absent
cognitive symptom signature, initial clinical presentation of FTD
may be confused with late-onset and primary psychiatric illness.
In fact, MBI was originally described by Taragano et al. as early
manifestations of FTD and, although they can be prodromal
symptoms of other forms of dementia, patients who present with
them (especially the ones without cognitive symptoms) are more
prone to develop FTD than AD (22, 60, 61).
Is Autolytic Behavior Less Frequent in Dementia
Patients With Comorbid Depression?
Consensus of opinion on the exceptionality of autolytical
behavior in these patients could not be generated (Table 3; S17).
This is a much-disputed issue probably because of the
existence of contradictory data. Some studies did not support
a significative relationship between dementia and autolytic
attempts (62). Others did identify an association between
dementia and suicidal ideation, attempt and/or completion,
especially soon after dementia diagnosis acknowledgment (54, 55,
63–65), which supports the idea that self-awareness of functional
decline increases suicidal risk and/or patients with deteriorated
brain function are more prone to catastrophic outcomes. In this
line, APA guidelines for depression consider that patients with
depression in dementia should be assessed for suicidality (20).
Other factors have been associated with suicidal risk in dementia
such as hopelessness, preserved insight, younger age, white race,
previous inpatient psychiatric hospitalization, antidepressant and
anxiolytic prescription, and resistance to anticholinesterases (54,
55).
III. Diagnostic Criteria for Depression in
Alzheimer’s Disease and Other Dementias
Are the Same Depression Diagnostic Criteria
Applicable to all Dementias or to Distinct Dementia
Stages?
Experts agreed on the need to establish specific depression
diagnostic criteria for the different entities that can present with
dementia (AD, Parkinson’s disease, FTD, etc.) as well as the stages
of the dementia syndrome (Table 4; S24 and S25) because of
the diverse repertoire of symptoms that varies according to the
degree of neurodegeneration (Table 3; S12 and S13).
Other authors have also claimed the urge to define consensus
criteria to diagnose depression in Alzheimer’s and other
dementias as it is currently underdiagnosed (7, 66). In the absence
of specific biomarkers for the daily practice, such diagnosis is
exclusively based on psychiatric interviews assessing a variety
of emotional and behavioral symptoms which then meet certain
pre-established criteria, such as those proposed by the National
Institutes of Mental Health (NIMH) and published in 2002 (67).
However, they remain somewhat unknown and not regularly
used by healthcare professionals outside Psychogeriatrics. In
contrast to the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) criteria for major depression in adults,
NIMH criteria for depression in AD (NIMH-dAD) require
the presence of at least 3 symptoms (and not 5) out of a
possible list of 10. This symptom list also contains some
modifications in comparison with the DSM-IV criteria such
as irritability and social isolation replacing loss of libido
and loss of pleasure upon social contact instead of loss of
interest (7).
Is It Possible to Differentiate Depression From Apathy
in AD Patients?
As agreed during this study, sadness, depressive cognitions, and
early-morning awakening are typically attributed to depression
in dementia and not apathy (Table 4; S20).
Apathy is the most prevalent comorbidity associated with
depression in AD. In the Cache County study, 27% of ADpatients
suffered from apathy and, of them, 40% also had depression
(7). Despite the high co-occurrence, apathy constitutes an
independent clinical entity from depression and has specific
clinical criteria (68, 69). Apart from the consensus symptoms
found in the present study, feeling of guilt, low self-esteem and
hopelessness are more common in depression than in apathy (7).
Can Neuroimaging Ease the Diagnosis of Depression
in AD?
Experts discarded structural neuroimaging techniques as useful
diagnostic resources (Table 4; S21) but collective opinion on
functional neuroimaging was not straightforward (Table 4; S22).
To date, there are no helpful biomarkers available to
diagnose depression in the presence or absence of dementia,
yet structural neuroimaging may be a valuable tool in ruling
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out the organic origin of depression. One of the main
criticisms of single photon emission computed (SPECT) or brain
positron emission (PET) tomography is that they lack enough
specificity (70).
Despite this, recent evidence does pave the way for the use of
such techniques and distinct surrogate biomarkers for depression
in AD patients. In their voxel-based morphometry analysis,
Karavasilis et al. suggested that Alzheimer and depression
comorbidities may be characterized by a specific pattern of
gray matter loss that coincides with anatomical regions of the
sensorimotor system and the right thalamus (71). In the same
line, and as discussed earlier on, Rashidi-Ranjbar et al.’s work
focused on two neuroimaging techniques, namely diffusion-
weighted imaging measuring white matter tract disruptions and
resting-state functional MRI, to provide important clues on both
functional and structural abnormalities shared by patients with
late-life depression and/or MCI (38). Other studies show that
[18F]-fluorodeoxyglucose (FDG) and amyloid-PET techniques
allow in vivo assessment of regional glucosemetabolism and beta-
amyloid plaque deposition, respectively, and their association
with cognitive, behavioral, and physical performance in MCI and
AD (72, 73).
Are There Other Useful Approaches to Diagnosing
Depression in Dementia?
Experts concurred that relatives can make a difference in refining
the diagnosis of depression in dementia (Table 4; S19) and that
the Cornell Scale for Depression in Dementia (CSDD) is useful
for screening patients in everyday clinical practice (Table 4; S26).
Older adults tend to minimize and rationalize their behavioral
and emotional symptoms by linking them to specific situations
or the mere aging process, yet depression is not a sine qua
non clinical feature of the latter. This biased normalization may
hinder the diagnosis of depression during patient interviews.
Therefore, data gathered from relatives and caregivers can aid the
task and complete the clinical information.
Among the plethora of available depression scales, CSDD
appeared to be the preferred one to detect and assess the severity
of depressive symptoms in older dementia patients (Table 4; S26),
whichmatches common recommendations fromAPA, EFNS and
the Institute for Clinical Systems Improvement (ICSI) guidelines
(16, 19–21). Other scales like the Geriatric Depression Scale
(GDS) or the Dementia Mood Assessment Scale (DMAS) may be
used in these cases, but CSDD shows the highest performance.
Moreover, it is a clinician-rated scale that involves caregivers,
which is an asset in this clinical context as it allows bypassing of
the aforementioned patient bias (6).
IV. Antidepressant Treatment for Dementia
and Alzheimer’s Disease Patients
Is Antidepressant Medication Effective in Treating
Depression in Elderly Patients With AD?
Consensus could be reached comfortably in regard to the efficacy
of antidepressants for this indication (Table 5; S28), although it
was also agreed that it is less effective in dementia patients than in
the absence of cognitive problems (Table 5; S41). Regarding the
treatment regimen, experts rejected prescribing both lower doses
of antidepressants and shorter treatment periods in AD patients
than in cognitively healthy patients (Table 5; S42 and S53).
Pharmacological therapy for depression in dementia is
recommended by most CPGs analyzed with some variations (17–
19, 57, 74). Whereas the World Health Organization (WHO)
guidelines consider that psychiatric drugs are warranted in cases
of moderate-severe depression (74), NICE emphasizes the need
to assess the risk-benefit ratio on a case-by-case basis (17).
Others such as the Fourth Canadian Consensus Conference
on the Diagnosis and Treatment of Dementia (CCCDTD4)
recommends drug therapy if non-pharmacological treatment
fails (57).
Among several reasons behind the disparity of results
from drug trials, it is interesting to mention the existence
of auto-limited cases of depression that ultimately resolve
without the need for treatment, which may justify the
high placebo effect observed in AD trials (75, 76). Also,
some studies show that antidepressant drug response varies
upon cognitive performance scores, whereas others do not
support such a claim (8, 77). Despite this, it follows from
this consensus that treatment nihilism should not be an
option in dementia patients, even if initial antidepressant
resistance occurs.
The fact that AD patients usually have several medical
comorbidities and therefore are exposed to polypharmacy
may lead to dosage adjustments compared to dementia-free
adults. Here, experts declared themselves against such principles
(Table 5; S42 and S53) to avoid the use of infratherapeutic doses
and the occurrence of treatment pseudoresistance.
Should Anti-dementia Cholinesterase Inhibitors Be
Used to Treat Depression in Alzheimer’s Patients?
Experts acknowledged the positive effect of cholinesterase
inhibitors (ChEIs) on depressive symptoms and their putative
synergism with antidepressants to treat depression in the context
of AD (Table 5; S29 and S37). However, the order in which
they should be administered could not be clarified (Table 5; S33
and S35).
In general, scarcity of trials dedicated to pharmacological
alternatives for depression in dementia seems the most plausible
explanation for a lack of consensus on these items of the
questionnaire. Add-on ChEIs in depressed older patients do not
seem to be more effective than antidepressants alone (78–80),
although one study suggests the opposite (81). Here, combination
therapy may have been disregarded due to safety concerns (drug-
drug interactions). For instance, anticholinergic antidepressants
may antagonize the effect of ChEIs (82), so concurrent use of
both drugs seems like a futile and unsafe therapeutic strategy,
especially in dementias that are characterized by cholinergic
deficiency such as AD or Lewy Body Disease. In relation to this,
CPGs highlight the significance of anticholinergic side effects
when choosing an antidepressant for dementia patients (16, 17,
19, 20, 57).
Regarding the benefits of ChEIs in depression (Table 5; S37),
the British Association for Psychopharmacology and several
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reports suggest that ChEIs may ameliorate neuropsychiatric
symptoms in Alzheimer’s or Lewy body dementia (58, 83–85).
Since the etiology of depression seems to be linked to the
neurodegenerative process, any improvements of the latter may
also be advantageous for depressive symptomatology.
Should Memantine Be Prescribed in Depressed
Alzheimer’s Disease Patients?
Apart from its indication for moderate to severe AD, no
consensus could be reached on the advantages (if any)
of memantine in depression treatment in these patients
(Table 5; S38).
Coadjuvant treatment with antidepressants and memantine
showed good depressive and cognitive outcomes in patients
with cognitive decline (86, 87). However, more studies are
needed to analyze whether combining ChEIs or memantine
with antidepressants has any added cognitive, affective, or
functional benefits.
Which Antidepressant Drug Groups Are More
Appropriate for Depressive Symptoms in Dementia?
In dementia, antidepressants with multiple mechanisms of
action (dual agents like venlafaxine/desvenlafaxine or duloxetine,
mirtazapine as well as tianeptine or the multimodal vortioxetine)
were preferred over others by this panel of experts (Table 5;
S30, S36, S47, S48, and S52). Unimodal SSRIs were considered
efficacious and well-tolerated drugs for this indication (Table 5;
S46), whereas tricyclic antidepressants (TCAs), including
nortriptyline, were not recommended (Table 5; S44 and S50).
Agomelatine and bupropion could not reach such a consensus
(Table 5; S49 and S51).
SSRIs are still the first-choice antidepressants in adult patients
with any comorbidities and in geriatric depression (47, 88). Some
studies point toward a higher effectiveness of the SSRI sertraline
compared with other antidepressants regulating more than one
neurotransmitter pathway (89), others found no advantages for
sertraline, fluoxetine, or mirtazapine vs. a placebo in cognitively
impaired patients with depression (75, 90). As suggested by
Lozupone and other experts, methodological discrepancies in
randomized controlled trials may be behind the disparity of
results among the few studies on antidepressant treatment in
AD (91), which adds to the challenge of establishing clear
recommendations. Prescription of SSRIs is also questionable
in other clinical conditions such as apathy. SSRIs and other
medications can have an apathogenic effect (92), so although
consensus could not be obtained regarding their use in patients
with significative apathy (Table 5; S45), it may be advisable to
monitor the symptoms and reduce the dose and/or replace them
with a non-SSRI alternative accordingly.
Most CPGs state that SSRIs (citalopram or sertraline)
and TCAs have similar efficacy, but SSRIs are preferred to
avoid anticholinergic side effects (6). Here, TCAs were not
recommended by the panel either, due to safety concerns.
Nortriptyline was not an exception, although it appears to be the
safest of its class (93). This consensus agreementmatches not only
CPG recommendations but several other published criteria for
drug prescription in the elderly like the Beers and STOPP-START
criteria (6, 94).
Along with SSRIs, consulted CPGs also recommend other
drugs like bupropion, venlafaxine, and mirtazapine, which shows
that there is no preference of one specific drug group over
others (6). This contrasts with the opinion of the experts in the
present study in favor of dual or multimodal antidepressants,
especially venlafaxine/desvenlafaxine, duloxetine, mirtazapine,
and vortioxetine. In a previous consensus on depression in
the elderly, experts had also agreed on the superior efficacy
of dual-action antidepressants compared to SSRIs in geriatric
depression (47). In fact, it has been proposed that a subgroup of
dementia patients with depression dominated by both affective
and psychological symptoms (pessimism and low self-esteem)
could benefit the most with mirtazapine. This subgroup of
patients did not present with sleep problems, which seems
counterintuitive since mirtazapine, with sedative properties, is
more effective in patients with such condition (95).
Specific opinions on bupropion and agomelatine among
participants were not as optimistic. We hypothesize that this
may be due to increased risk of convulsions associated with
bupropion uptake. However, its non-serotonergic and rather
activating effects (96) would make it suitable for AD, where more
noradrenergic symptoms prevail, or in the apathy syndrome in
AD. No evidence could be found to explain the lack of consensus
toward agomelatine, so we can only speculate on cost-associated
causes or clinical habits.
Are Antidepressant Drugs With Precognitive Actions
the Treatment of Choice in Alzheimer’s Disease?
Experts unanimously considered that the gold standard
antidepressant drugs in AD are the ones that improve cognitive
function in geriatric depression (Table 5; S40). Of them, dual
(duloxetine) and tianeptine as well as multimodal agents
(vortioxetine) show a good efficacy and tolerability profile
(Table 5; S30, S47, and S52).
Over recent years, awareness of the anticholinergic side effects
of paroxetine and TCAs has increased as they compromise
cognition (93). This becomes an issue of greater importance
in cognitively impaired and dementia patients. Because of that,
much attention has been drawn to the use of the antidepressant
drugs with precognitive actions.
The number of studies addressing the efficacy and safety
of these drugs in depression and dementia is still limited. A
meta-analysis of 3 controlled trials concluded that vortioxetine,
aside from its efficacy in depression, significantly improves
cognitive function compared with duloxetine (97). An
observational study in AD found significative cognitive
advantages with vortioxetine in contrast to other antidepressants.
However, the control group of the comparative arm was very
heterogeneous and vortioxetine’s efficacy was not directly
tested against other drugs with precognitive actions like
tianeptine (98).
Unlike other antidepressants, tianeptine has anxiolytic
properties and can also improve somatic symptoms (99).
In depression and AD, it shows higher tolerability and,
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consequently, higher patient compliance than other agents such
as fluoxetine (100).
Should Non-pharmacological Approaches Be
Considered in Depressed and Dementia Patients?
Experts reckoned that both physical activity and psychological
interventions (social contact, reminiscence therapy, and
cognitive rehabilitation) have antidepressant efficacy
(Table 5; S27 and S31), yet this may not be enough as
to warrant their application as an initial approach in
dementia (Table 5; S32).
Some results from previous meta-analysis support expert
opinion collected through this Delphi questionnaire but others
point in different directions. The one published in 2015 by
Forbes et al. found that evidence of the effects of physical
activity on depression is inconclusive (101). Another one from
2019 suggested it may be beneficial for cognition and activities
of daily living (ADL) of older individuals with dementia, but
depression levels did not change (102). Conversely, another
systematic review and meta-analysis released the same year did
find a positive effect of home-based exercise on neuropsychiatric
symptoms of dementia, ADL and physical fitness of older adults
with dementia living at home as well as a reduction in caregiver’s
burden (103).
Similar to antidepressant drugs, it is worth mentioning
that physical exercise cannot be regarded as a uniform
whole, so that efficacy and safety assessment is a challenging
issue that may explain discrepancies among studies. The
same applies to other types of non-pharmacological
options such as reminiscence therapy, which has significant
scientific support in AD-related depression (104). Some
CPGs like APA’s and NICE’s also recommend the inclusion
of a variety of non-pharmacological options like the
ones already mentioned or cognitive behavioral, animal-
assisted, stimulation-oriented, or multi-sensory stimulation
therapy (6).
Although experts recognized their efficacy, specific knowledge
gaps and/or limited availability of non-pharmacological
approaches may deter them from using them in the first
place. On one hand, other experts proposed that these
patients should be managed by non-pharmacological means
initially unless presenting with severe depression or an
inability to receive such therapies (105). On the other hand,
CHROME criteria state that there are several reasons why
psychiatric drugs should be applied from the beginning
such as the previously observed good response to them or
having a personal history of severe and recurrent depressive
episodes (106).
Is Electroconvulsive Therapy an Acceptable
Therapeutic Choice in Dementia?
Electroconvulsive therapy (ECT) could not be recommended nor
rejected as a valid alternative for antidepressant refractory cases
(Table 5; S43).
ECT is widely used in severe and drug-resistant cases of
depression (47) and APA guidelines claim its use in certain
cases of depression in those with dementia (20). Non-psychiatrist
physicians may be unfamiliar with it, which could explain the
larger proportion of neurologists in the panel in disagreement
with this technique (data not shown). In spite of the existence
of some cognitive adverse effects in the first 3 days post-
ECT, meta-analytical data from depressed patients demonstrated
that working and anterograde memory as well as processing
speed (among other executive functions) improved after 15 days
compared with baseline levels (107).
CONCLUSIONS
An ad-hoc questionnaire was designed to gather opinion from
expert physicians working in the field of neurodegenerative
disease. Consensus agreement could be reached for most of
the items addressing risk factors, clinical parameters, diagnostic
criteria, and treatment of depression in AD and other dementias
(Figure 2).
Depression that initiates in older adults, with or without
subjective memory loss complaints, was considered an early
sign (prodromal) and/or a dementia predisposition (risk)
factor. Therefore, routine check-ups of depressed patients over
50 should be performed. Conversely, in already diagnosed
dementia patients, experts agreed that depression would not
only be an emotionally reactive mental disturbance related
to the experimented impairment, although the influence of
social environment on its onset cannot be dismissed. Instead,
other neurobiological factors such as vascular damage would
play a more prominent role. Once dementia is established,
it was suggested that depressive episodes would accelerate
dementia progression whereas antidepressants would have the
opposite effect.
According to expert opinion, the existence of cognitive
symptoms specifically related to depression undermines
neuropsychological assessment in already demented patients.
Also, caution should be taken when confirming the diagnosis
of dementia, which should be postponed until treatment with
antidepressants has been initiated and both depressive and
cognitive symptoms have been followed for a reasonable period
of time.
In advanced dementia patients, referring to “symptoms of
depression” seemedmore appropriate than the term “depression”
or “depressive disorder” because there are no formal diagnostic
criteria for depression in late-stage dementia. As observed in
clinical practice, experts remarked that symptoms in such stages
of dementia include reversal of sleep-wake cycle, aggressive
behavior, and agitation. In contrast, depression in early dementia
is characterized by somatic symptoms as in the general adult
population: Daily mood fluctuations, early-morning awakening,
psychomotor retardation, or anorexia with weight loss. Also,
feeling sad, having depressive thoughts, and waking up early in
the morning were found to be suggestive of depression and not
apathy. To aid diagnosis of depression in dementia sufferers,
CSDD scale and information from relatives were found useful,
whereas structural neuroimaging techniques were discarded.
Frontiers in Psychiatry | www.frontiersin.org 12 February 2021 | Volume 12 | Article 638651
Agüera-Ortiz et al. Expert Consensus on Depression in Alzheimer’s Disease
Unanimous consensus could be reached on the efficacy of
antidepressants, although it may be lower than in cognitively
healthy patients. Also, neither the dose nor the treatment
period should be necessarily different in dementia patients.
Anti-dementia ChEIs may have a positive effect on depressive
symptoms and a synergistic effect together with antidepressants.
However, their recommended order of administration
remained unclear.
In AD, antidepressants of choice were those that improve
cognitive function and/or have a dual or multimodal mode
of action, namely duloxetine, venlafaxine/desvenlafaxine,
tianeptine, vortioxetine, and mirtazapine. SSRIs may also be
used in AD patients. TCAs were not regarded as safe agents for
this indication. Regarding non-pharmacological approaches, the
usefulness of exercise and psychological interventions based on
social contact, reminiscence therapy, and cognitive rehabilitation
was ratified, although their stand-alone use was not considered
appropriate as an initial treatment.
The opinions summarized above mark a step forward
and contribute to the field of depression in the context of
dementia. They provide knowledge and clinical advice beyond
limited CPG recommendations on diagnosis and treatment
for such patients. They also give clarity regarding the most
controversial etiological and clinical aspects of depression
and dementia. However, future endeavors should continue
addressing several unmet clinical needs, especially diagnostic
criteria for depression and antidepressant tailored therapies
in dementia patients in contrast to younger or cognitively
healthy adults.
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28. Brzezińska A, Bourke J, Rivera-Hernández R, Tsolaki M, Wozniak J,
Kazmierski J. Depression in dementia or dementia in depression? Systematic
review of studies and hypotheses. Curr Alzheimer Res. (2020) 17:16–
28. doi: 10.2174/1567205017666200217104114
29. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA.
Midlife vs late-life depressive symptoms and risk of dementia. Arch Gen
Psychiatry. (2012) 69:493–8. doi: 10.1001/archgenpsychiatry.2011.1481
30. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a
modifiable factor to decrease the risk of dementia. Transl Psychiatry. (2017)
7:e1117. doi: 10.1038/tp.2017.90
31. Kaup AR, Byers AL, Falvey C, Simonsick EM, Satterfield S,
Ayonayon HN, et al. Trajectories of depressive symptoms in
older adults and risk of dementia. JAMA Psychiatry. (2016)
73:525–31. doi: 10.1001/jamapsychiatry.2016.0004
32. Barca ML, Persson K, Eldholm R, Benth JŠ, Kersten H, Knapskog
AB, et al. Trajectories of depressive symptoms and their relationship
to the progression of dementia. J Affect Disord. (2017) 222:146–
52. doi: 10.1016/j.jad.2017.07.008
33. Leoutsakos JMS, Forrester SN, Corcoran CD, Norton MC, Rabins P V.,
Steinberg MI, et al. Latent classes of course in Alzheimer’s disease and
predictors: the cache county dementia progression study. Int J Geriatr
Psychiatry. (2015) 30:824–32. doi: 10.1002/gps.4221
34. Rapp MA, Schnaider-Beeri M, Wysocki M, Guerrero-Berroa E, Grossman
HT, Heinz A, et al. Cognitive decline in patients with dementia as
a function of depression. Am J Geriatr Psychiatry. (2011) 19:357–
63. doi: 10.1097/JGP.0b013e3181e898d0
35. Wilson RS, Barnes LL, Mendes De Leon CF, Aggarwal NT, Schneider
JS, Bach J, et al. Depressive symptoms, cognitive decline, and risk of
AD in older persons. Neurology. (2002) 59:364–70. doi: 10.1212/WNL.
59.3.364
36. Enache D, Winblad B, Aarsland D. Depression in dementia: Epidemiology,
mechanisms, and treatment. Curr Opin Psychiatry. (2011) 24:461–
72. doi: 10.1097/YCO.0b013e32834bb9d4
37. Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds
CF, et al. Pathways linking late-life depression to persistent cognitive
impairment and dementia. Dialogues Clin Neurosci. (2008) 10:345–
57. doi: 10.31887/DCNS.2008.10.3/mabutters
38. Rashidi-Ranjbar N, Miranda D, Butters MA, Mulsant BH, Voineskos
AN. Evidence for structural and functional alterations of frontal-executive
and corticolimbic circuits in late-life depression and relationship to mild
cognitive impairment and dementia: a systematic review. Front Neurosci.
(2020) 14:253. doi: 10.3389/fnins.2020.00253
39. Linnemann C, Lang UE. Pathways connecting late-life depression and
dementia. Front Pharmacol. (2020) 11:279. doi: 10.3389/fphar.2020.00279
40. Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Impact
of SSRI therapy on risk of conversion from mild cognitive impairment
to Alzheimer’s dementia in individuals with previous depression. Am J
Psychiatry. (2018) 175:232–41. doi: 10.1176/appi.ajp.2017.17040404
41. Moraros J, Nwankwo C, Patten SB, Mousseau DD. The association of
antidepressant drug usage with cognitive impairment or dementia, including
Alzheimer disease: a systematic review and meta-analysis. Depress Anxiety.
(2017) 34:217–26. doi: 10.1002/da.22584
42. Brailean A, Aartsen MJ, Muniz-Terrera G, Prince M, Prina AM, Comijs HC,
et al. Longitudinal associations between late-life depression dimensions and
cognitive functioning: a cross-domain latent growth curve analysis. Psychol
Med. (2017) 47:690–702. doi: 10.1017/S003329171600297X
43. Gallagher D, Kiss A, Lanctot K, Herrmann N. Depression and risk of
Alzheimer dementia: a longitudinal analysis to determine predictors of
increased risk among older adults with depression. Am J Geriatr Psychiatry.
(2018) 26:819–27. doi: 10.1016/j.jagp.2018.05.002
44. Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, Mueller SG,
et al. Cortical atrophy is associated with accelerated cognitive decline in
mild cognitive impairment with subsyndromal depression. Am J Geriatr
Psychiatry. (2017) 25:980–91. doi: 10.1016/j.jagp.2017.04.011
45. Martín-Carrasco M, Agüera-Ortiz L, Caballero-Martínez L, Cervilla-
Ballesteros J, Menchón-Magriñá JM, Montejo-González AL, et al. Consensus
of the SEPG on depression in the elderly. Actas Esp Psiquiatr. (2011) 39:20–
31.
46. Steck N, Cooper C, Orgeta V. Investigation of possible risk factors for
depression in Alzheimer’s disease: a systematic review of the evidence. J Affect
Disord. (2018) 236:149–56. doi: 10.1016/j.jad.2018.04.034
47. Agüera-Ortiz L, Claver-Martín MD, Franco-Fernández MD, López-Álvarez
J, Martín-Carrasco M, Ramos-García MI, et al. Depression in the Elderly.
consensus statement of the Spanish Psychogeriatric Association. Front
Psychiatry. (2020) 11:380. doi: 10.3389/fpsyt.2020.00380
48. Köhler S, Van Boxtel M, Jolles J, Verhey F. Depressive symptoms and risk
for dementia: a 9-year follow-up of the maastricht aging study. Am J Geriatr
Psychiatry. (2011) 19:902–5. doi: 10.1097/JGP.0b013e31821f1b6a
49. Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA,
Bennett DA. Depressive symptoms, clinical AD, and cortical
plaques and tangles in older persons. Neurology. (2003)
61:1102–7. doi: 10.1212/01.WNL.0000092914.04345.97
50. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive
symptoms, vascular disease, and mild cognitive impairment: findings from
the cardiovascular health study. Arch Gen Psychiatry. (2006) 63:273–
80. doi: 10.1001/archpsyc.63.3.273
51. Van Uden IWM, Van Der Holst HM, Van Leijsen EMC, Tuladhar AM,
Van Norden AGW, De Laat KF, et al. Late-onset depressive symptoms
increase the risk of dementia in small vessel disease. Neurology. (2016)
87:1102–9. doi: 10.1212/WNL.0000000000003089
52. Vik-Mo AO, Giil LM, Ballard C, Aarsland D. Course of neuropsychiatric
symptoms in dementia: 5-year longitudinal study. Int J Geriatr Psychiatry.
(2018) 33:1361–9. doi: 10.1002/gps.4933
53. Gonfrier S, Andrieu S, Renaud D, Vellas B, Robert P. Course of
neuropsychiatric symptoms during a 4-year follow up in the REAL-FR
cohort. J Nutr Heal Aging. (2012) 16:134–7. doi: 10.1007/s12603-011-0147-9
54. Seyfried LS, Kales HC, Ignacio R V., Conwell Y, Valenstein M. Predictors
of suicide in patients with dementia. Alzheimer’s Dement. (2011) 7:567–
73. doi: 10.1016/j.jalz.2011.01.006
55. Haw C, Harwood D, Hawton K. Dementia and suicidal
behavior: a review of the literature. Int Psychogeriatrics. (2009)
21:440–53. doi: 10.1017/S1041610209009065
Frontiers in Psychiatry | www.frontiersin.org 14 February 2021 | Volume 12 | Article 638651
Agüera-Ortiz et al. Expert Consensus on Depression in Alzheimer’s Disease
56. Kang H, Zhao F, You L, Giorgetta C, Venkatesh D, Sarkhel S, et al. Pseudo-
dementia: A neuropsychological review. Ann Indian Acad Neurol. (2014)
17:147–54. doi: 10.4103/0972-2327.132613
57. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood
K, et al. Recommendations of the 4th Canadian consensus conference on
the diagnosis and treatment of dementia (CCCDTD4). Can Geriatr J. (2012)
15:120–6. doi: 10.5770/cgj.15.49
58. O’Brien JT, Burns A. Clinical practice with anti-dementia
drugs: a revised (second) consensus statement from the British
Association for Psychopharmacology. J Psychopharmacol. (2011)
25:997–1019. doi: 10.1177/0269881110387547
59. Collins JD, Henley SMD, Suárez-González A. A systematic review of
the prevalence of depression, anxiety, and apathy in frontotemporal
dementia, atypical and young-onset Alzheimer’s disease, and inherited
dementia. Int Psychogeriatrics. (2020) 1–20. doi: 10.1017/S1041610
220001118. [Epub ahead of print].
60. Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM,
Loñ L, et al. Mild behavioral impairment and risk of dementia: a
prospective cohort study of 358 patients. J Clin Psychiatry. (2009) 70:584–
92. doi: 10.4088/JCP.08m04181
61. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesaña-Diaz E.
A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline
in the treatment of major depression complicating Alzheimer’s disease.
Psychosomatics. (1997) 38:246–52. doi: 10.1016/S0033-3182(97)71461-0
62. Wiktorsson S, Runeson B, Skoog I, Östling S, Waern M. Attempted suicide
in the elderly: characteristics of suicide attempters 70 years and older and
a general population comparison group. Am J Geriatr Psychiatry. (2010)
18:57–67. doi: 10.1097/JGP.0b013e3181bd1c13
63. Cui R, Maxfield M, Fiske A. Dementia-related anxiety and coping styles
associated with suicidal ideation. Aging Ment Heal. (2019) 24:1912–
5. doi: 10.1080/13607863.2019.1636205
64. Álvarez Muñoz FJ, Rubio-Aparicio M, Gurillo Muñoz P, García Herrero
AM, Sánchez-Meca J, Navarro-Mateu F. Suicide and dementia: systematic
review and meta-analysis. Rev Psiquiatr Salud Ment. (2020) 13:213–
27. doi: 10.1016/j.rpsmen.2020.04.006
65. Greene RD, Cook A, Nowaskie D, Wang S. Neurological
changes and depression: 2020. update. Clin Geriatr Med. (2020)
36:297–313. doi: 10.1016/j.cger.2019.11.009
66. Spanish Psychogeriatric Society (SEPG). [Consensus on Depression in
the Elderly-2nd Edition]. SL MAS& S, editor. Barcelona: Marketing Aid
Systems & Services SL (2019). Available online at: http://www.sepg.es/
2ConsensoSobreDepresion (accessed July 15, 2020).
67. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS,
Breitner JC, et al. Provisional diagnostic criteria for depression
of Alzheimer disease. Am J Geriatr Psychiatry. (2002) 10:125–
8. doi: 10.1097/00019442-200203000-00004
68. Levy R, Dubois B. Apathy and the functional anatomy of the
prefrontal cortex-basal ganglia circuits. Cereb Cortex. (2006)
16:916–28. doi: 10.1093/cercor/bhj043
69. Robert P, Lanctôt KL, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco
M, et al. Is it time to revise the diagnostic criteria for apathy in brain
disorders? The 2018 international consensus group. Eur Psychiatry. (2018)
54:71–6. doi: 10.1016/j.eurpsy.2018.07.008
70. Taylor WD. Depression in the elderly. N Engl J Med. (2014) 371:1228–
36. doi: 10.1056/NEJMcp1402180
71. Karavasilis E, Parthimos TP, Papatriantafyllou JD, Papageorgiou SG,
Kapsas G, Papanicolaou AC, et al. A specific pattern of gray matter
atrophy in Alzheimer’s disease with depression. J Neurol. (2017) 264:2101–
9. doi: 10.1007/s00415-017-8603-z
72. Lauretani F, Ruffini L, Scarlattei M, Maggio M. Relationship between
comprehensive geriatric assessment and amyloid PET in older persons with
MCI. BMC Geriatr. (2020) 20:337. doi: 10.1186/s12877-020-01746-x
73. HedderichDM,Drost R, Goldhardt O, OrtnerM,Müller-Sarnowski F, Diehl-
Schmid J, et al. Regional cerebral associations between psychometric tests
and imaging biomarkers in Alzheimer’s disease. Front Psychiatry. (2020)
11:793. doi: 10.3389/fpsyt.2020.00793
74. Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, van
Ommeren M, et al. Evidence-based guidelines for mental,
neurological, and substance use disorders in low- and middle-income
countries: summary of WHO recommendations. PLoS Med. (2011)
8:e1001122. doi: 10.1371/journal.pmed.1001122
75. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-
controlled study of fluoxetine in depressed patients with Alzheimer’s
disease. Int Psychogeriatrics. (2001) 13:233–40. doi: 10.1017/S1041610
20100761X
76. Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of Antidepressants
for depression in Alzheimer’s disease: systematic review and meta-analysis. J
Alzheimer’s Dis. (2017) 58:725–33. doi: 10.3233/JAD-161247
77. Koenig AM, Butters MA, Begley A, Ogbagaber S, Wahed AS, Reynolds
CF. Response to antidepressant medications in late-life depression across
the spectrum of cognitive functioning. J Clin Psychiatry. (2014) 75:e100–
7. doi: 10.4088/JCP.13m08442
78. Holtzheimer PE, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter
K, et al. A double blind, placebo-controlled pilot study of galantamine
augmentation of antidepressant treatment in older adults with major
depression. Int J Geriatr Psychiatry. (2008) 23:625–31. doi: 10.1002/gps.1951
79. McDermott CL, Gray SL. Cholinesterase inhibitor adjunctive therapy
for cognitive impairment and depressive symptoms in older adults with
depression. Ann Pharmacother. (2012) 46:599–605. doi: 10.1345/aph.1Q445
80. Devanand DP, Pelton GH, D’Antonio K, Ciarleglio A, Scodes J,
Andrews H, et al. Donepezil treatment in patients with depression
and cognitive impairment on stable antidepressant treatment:
a randomized controlled trial. Am J Geriatr Psychiatry. (2018)
26:1050–60. doi: 10.1016/j.jagp.2018.05.008
81. Pelton GH, Harper OL, Tabert MH, Sackeim HA, Scarmeas N, Roose SP,
et al. Randomized double-blind placebo-controlled donepezil augmentation
in antidepressant-treated elderly patients with depression and cognitive
impairment: a pilot study. Int J Geriatr Psychiatry. (2008) 23:670–
6. doi: 10.1002/gps.1958
82. Johnell K, Fastbom J. Concurrent use of anticholinergic drugs
and cholinesterase inhibitors: register-based study of over
700 000 elderly patients. Drugs and Aging. (2008) 25:871–
7. doi: 10.2165/00002512-200825100-00006
83. Cummings JL, McRae T, Zhang R. Effects of donepezil on
neuropsychiatric symptoms in patients with dementia and
severe behavioral disorders. Am J Geriatr Psychiatry. (2006)
14:605–12. doi: 10.1097/01.JGP.0000221293.91312.d3
84. Spalletta G, Gianni W, Giubilei F, Casini AR, Sancesario G, Caltagirone C,
et al. Rivastigmine patch ameliorates depression in Mild AD: preliminary
evidence from a 6-month open-label observational study. Alzheimer Dis
Assoc Disord. (2013) 27:289–91. doi: 10.1097/WAD.0b013e318260ab0a
85. Graipaspong N, Thaipisuttikul P, Vallipakorn SA. Cholinesterase inhibitors
and behavioral & psychological symptoms of Alzheimer’s disease. J Med
Assoc Thai. (2016) 99:433–40.
86. Pelton GH, Harper OL, Roose SP, Marder K, D’Antonio K, Devanand DP.
Combined treatment with memantine/es-citalopram for older depressed
patients with cognitive impairment: A pilot study. Int J Geriatr Psychiatry.
(2016) 31:648–55. doi: 10.1002/gps.4375
87. Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda
A, et al. A randomized double-blind placebo-controlled trial of combined
escitalopram and memantine for older adults with major depression and
subjective memory complaints. Am J Geriatr Psychiatry. (2020) 28:178–
90. doi: 10.1016/j.jagp.2019.08.011
88. Price A, Rayner L, Okon-Rocha E, Evans A, Valsraj K, Higginson IJ, et al.
Antidepressants for the treatment of depression in neurological disorders: a
systematic review andmeta-analysis of randomised controlled trials. J Neurol
Neurosurg Psychiatry. (2011) 82:914–23. doi: 10.1136/jnnp.2010.230862
89. Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi
MB, et al. Comparison of sertraline, venlafaxine and desipramine effects on
depression, cognition and the daily living activities in alzheimer patients.
Pharmacopsychiatry. (2014) 47:131–40. doi: 10.1055/s-0034-1377041
90. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study
of the use of antidepressants for depression in dementia: the HTA-SADD
trial- A multicentre, randomised, double-blind, placebo-controlled trial of
the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Health Technol Assess. (2013) 17:1–43. doi: 10.3310/hta17070
Frontiers in Psychiatry | www.frontiersin.org 15 February 2021 | Volume 12 | Article 638651
Agüera-Ortiz et al. Expert Consensus on Depression in Alzheimer’s Disease
91. Lozupone M, La Montagna M, D’Urso F, Piccininni C, Sardone R, Dibello
V, et al. Pharmacotherapy for the treatment of depression in patients with
alzheimer’s disease: a treatment-resistant depressive disorder. Expert Opin
Pharmacother. (2018) 19:823–42. doi: 10.1080/14656566.2018.1471136
92. Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry.
(2010) 7:14–8.
93. Starkstein SE, Brockman S. Management of depression in Parkinson’s
disease: a systematic review. Mov Disord Clin Pract. (2017) 4:470–
7. doi: 10.1002/mdc3.12507
94. Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-
Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. Mejorando la
prescripción de medicamentos en las personas mayores: Una nueva edición
de los criterios STOPP-START. Rev Esp Geriatr Gerontol. (2015) 50:89–
96. doi: 10.1016/j.regg.2014.10.005
95. Zuidersma M, Chua KC, Hellier J, Voshaar RO, Banerjee S. Sertraline and
mirtazapine versus placebo in subgroups of depression in dementia: findings
from the HTA-SADD Randomized controlled trial. Am J Geriatr Psychiatry.
(2019) 27:920–31. doi: 10.1016/j.jagp.2019.03.021
96. European Medicines Agency. Bupropion Hydrochloride. Available online
at: https://www.ema.europa.eu/en/medicines/human/referrals/bupropion-
hydrochloride#all-documents-section (accessed October 4, 2020).
97. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects
sof vortioxetine on cognitive function in patients with major depressive
disorder: a meta-analysis of three randomized controlled trials. Int J
Neuropsychopharmacol. (2016) 19:pyw055. doi: 10.1093/ijnp/pyw055
98. Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment effects of
vortioxetine on cognitive functions in mild alzheimer’s disease patients with
depressive symptoms: a 12 month, open-label, observational study. J Prev
Alzheimer’s Dis. (2019) 6:192–7. doi: 10.14283/jpad.2019.24
99. Alamo C, García-Garcia P, Lopez-Muñoz F, Zaragozá C. Tianeptine, an
atypical pharmacological approach to depression. Rev Psiquiatr Salud Ment.
(2019) 12:170–86. doi: 10.1016/j.rpsmen.2018.09.001
100. Sobow TM, Maczkiewicz M, Kloszewska I. Tianeptine versus fluoxetine in
the treatment of depression complicating Alzheimer’s disease. Int J Geriatr
Psychiatry. (2001) 16:1108–9. doi: 10.1002/gps.457
101. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs
for people with dementia. Cochr Datab Syst Rev. (2015) 2015:CD006489.
doi: 10.1002/14651858.CD006489.pub4
102. Li X, Guo R, Wei Z, Jia J, Wei C. Effectiveness of exercise programs
on patients with dementia: a systematic review and meta-analysis of
randomized controlled trials. Biomed Res Int. (2019). 2019:2308475.
doi: 10.1155/2019/2308475
103. Almeida SIL de, Gomes da Silva M, Marques ASP de D. Home-based
physical activity programs for people with dementia: systematic review and
meta-analysis. Gerontologist. (2019) 60:600–8. doi: 10.1093/geront/gnz176
104. Lök N, Bademli K, Selçuk-Tosun A. The effect of reminiscence therapy
on cognitive functions, depression, and quality of life in Alzheimer
patients: Randomized controlled trial. Int J Geriatr Psychiatry. (2019) 34:47–
53. doi: 10.1002/gps.4980
105. Gutzmann H, Qazi A. Depression bei Demenz. Z Gerontol
Geriatr. (2015) 48:305–11. doi: 10.1007/s00391-015-
0898-8
106. Olazarán-Rodríguez J, López-Álvarez J, Agüera-Ortiz LF, López-Arrieta
JM, Beltrán-Aguirre JL, García-García P, et al. Criterios CHROME para la
acreditación de centros libres de sujeciones químicas y para una prescripción de
psicofármacos de calidad. (2016). Available online at: www.viguera.com/sepg
(accessed July 14, 2020).
107. SemkovskaM,McLoughlin DM. Objective cognitive performance associated
with electroconvulsive therapy for depression: A systematic review andmeta-
analysis. Biol Psychiatry. (2010) 68:568–77. doi: 10.1016/j.biopsych.2010.
06.009
Conflict of Interest: LA-O has received grants from and served as consultant,
advisor, or CME speaker for Janssen-Cilag, Exeltis, Lundbeck, Pfizer,
Neuraxpharm, Sanofi-Aventis, and Servier. JO has received honoraria to
participate in courses, lectures, congresses, and scientific advisory boards from
several pharmaceutical companies including Exeltis, Janssen, Lundbeck, Angelini,
Pfizer, Otsuka, and Esteve. JL-Á has prepared a monograph on this Delphi
consensus with the financial help of Exeltis Pharmaceuticals Holding, S.L. JM
has received grants from and served as consultant, advisor, or CME speaker
for Almirall, Angelini, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer,
GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Qualigen, Recordati,
Sanofi-Aventis, Servier, and the Spanish Ministry of Science and Innovation
(CIBERSAM). CP has received honoraria to participate in courses and lectures
and has been invited to congresses and scientific advisory boards from several
pharmaceutical companies including Exeltis, Janssen, Lundbeck, Angelini, Pfizer,
and Casen.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Agüera-Ortiz, García-Ramos, Grandas Pérez, López-Álvarez,
Montes Rodríguez, Olazarán Rodríguez, Olivera Pueyo, Pelegrin Valero and Porta-
Etessam. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org 16 February 2021 | Volume 12 | Article 638651
